Esperion Therapeutics Inc. (NASDAQ: ESPR) on May 19, 2023, started off the session at the price of $1.73, plunging -3.81% from the previous trading day. During the day, the shares moved up to $1.81 and dropped to $1.63 before settling in for the closing price of $1.71. Within the past 52 weeks, ESPR’s price has moved between $1.12 and $8.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 62.20%. With a float of $73.15 million, this company’s outstanding shares have now reached $78.44 million.
Let’s determine the extent of company efficiency that accounts for 199 employees. In terms of profitability, gross margin is +63.61, operating margin of -237.83, and the pretax margin is -309.58.
Esperion Therapeutics Inc. (ESPR) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Esperion Therapeutics Inc. is 0.60%, while institutional ownership is 87.80%. The most recent insider transaction that took place on May 17, was worth 356. In this transaction Chief Commercial Officer of this company sold 219 shares at a rate of $1.62, taking the stock ownership to the 70,012 shares. Before that another transaction happened on May 11, when Company’s Director bought 23,091 for $1.57, making the entire transaction worth $36,285. This insider now owns 36,500 shares in total.
Esperion Therapeutics Inc. (ESPR) Recent Fiscal highlights
As on 3/30/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.79 earnings per share (EPS) for the period falling under the consensus outlook (set at -$0.65) by -$0.14. This company achieved a net margin of -309.58. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 62.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 12.80% growth over the previous five years of trading.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Trading Performance Indicators
Esperion Therapeutics Inc. (ESPR) is currently performing well based on its current performance indicators. A quick ratio of 2.20 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.40, a number that is poised to hit -0.60 in the next quarter and is forecasted to reach -0.04 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc. (ESPR)
Looking closely at Esperion Therapeutics Inc. (NASDAQ: ESPR), its last 5-days average volume was 2.3 million, which is a drop from its year-to-date volume of 3.26 million. As of the previous 9 days, the stock’s Stochastic %D was 76.94%. Additionally, its Average True Range was 0.18.
During the past 100 days, Esperion Therapeutics Inc.’s (ESPR) raw stochastic average was set at 8.27%, which indicates a significant decrease from 66.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.76% in the past 14 days, which was lower than the 146.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6765, while its 200-day Moving Average is $5.5580. However, in the short run, Esperion Therapeutics Inc.’s stock first resistance to watch stands at $1.7567. Second resistance stands at $1.8733. The third major resistance level sits at $1.9367. If the price goes on to break the first support level at $1.5767, it is likely to go to the next support level at $1.5133. Now, if the price goes above the second support level, the third support stands at $1.3967.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Key Stats
Market capitalization of the company is 161.51 million based on 94,713K outstanding shares. Right now, sales total 75,480 K and income totals -233,660 K. The company made 24,330 K in profit during its latest quarter, and -61,720 K in sales during its previous quarter.
